Molecular Mechanisms of Susceptibility to Drug Use.
Project Number7K01DA051598-06
Former Number5K01DA051598-05
Contact PI/Project LeaderGROMAN, STEPHANIE MARY
Awardee OrganizationUNIVERSITY OF CHICAGO
Description
Abstract Text
PROJECT SUMMARY / ABSTRACT
The transition from drug use to abuse and, eventually, to dependence may be mediated by biological factors
that are present prior to drug use. Although chronic exposure to drugs of abuse is known to disrupt many
signaling pathways, little is known about the molecular mechanisms that mediate addiction susceptibility. There
is considerable interest in identifying early biomarkers for addiction susceptibility to improve addiction
prevention strategies. Most studies have been conducted in substance-dependent individuals where the
dissociation between ‘susceptibility’ and ‘consequence’ is ambiguous. I have recently identified a behavioral
phenotype in rats that reliably predicts future drug-taking behaviors and identified three proteins as potential
mediators of addiction susceptibility: sorting nexin 1 (SNX1), ryanodine receptor 2 (RYR2), and ataxin 2-like
(ATXN2L). These proteins are involved in intracellular trafficking, calcium signaling and cytoskeleton
reorganization, and have been previously linked to addiction. Precisely how differences in expression of these
proteins impact the signaling cascades underlying addiction susceptibility is not known. The overarching goal
of this proposal is to determine the functional and molecular role of proteins that mediate addiction
susceptibility and investigate how these factors are mechanistically linked to genetic and/or environmental
components of risk for addiction. To accomplish this goal, the proposed research will combine sophisticated
behavioral and computational assessments with viral, proteomic and bioinformatic approaches. In Aim 1 I will
use an inducible and reversible viral construct to bi-directionally manipulate expression of SNX1, RYR2, and
ATXN2L and also determine how changes in expression of SNX1, RYR2, and ATXN2L alter
methamphetamine self-administration and protein signaling mechanisms. In Aim 2 I will determine if variation
in the expression of SNX1, RYR2, and ATXN2L is altered in a model of genetic addiction susceptibility and is
associated with increased addiction risk. In Aim 3 I will determine if variation in expression of SNX1, RYR2,
and ATXN2L is altered in a model of environmental addiction susceptibility and is associated with increased
addiction risk. Completion of these aims will generate new insights into the signaling mechanisms of addiction
susceptibility that could identify early biological markers of risk for addiction and improve current strategies for
addiction prevention. The Principal Investigator will receive mentorship and technical training in viral and
proteomic technologies by experts in cell signaling and cellular mechanisms, and viral technologies in
motivated behaviors. Yale University and the Department Psychiatry provide exceptional facilities and
resources for completing the proposed experiments, as well as having an exceptional reputation and track
record for mentoring and transitioning early-stage investigators in to independent investigators. The proposed
training, education and research will provide the PI with the technical and professional training to become a
successful, independent addiction investigator.
Public Health Relevance Statement
NARRATIVE
Only a subset of individuals that use drugs of abuse will develop an addiction, suggesting that the transition
from drug use to dependence may be mediated by behavioral or biological factors that influence the likelihood
of an individual to develop an addiction. Using computationally-derived decision-making phenotypes, this
proposal seeks to identify and verify the signaling pathways that confer risk for drug use and to determine if
these molecular disruptions are linked to genetic and/or environmental components of risk for drug-taking
behaviors. These results will identify novel protein targets to aid in the development of more precise and direct
prevention strategies for methamphetamine addiction.
No Sub Projects information available for 7K01DA051598-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7K01DA051598-06
Patents
No Patents information available for 7K01DA051598-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7K01DA051598-06
Clinical Studies
No Clinical Studies information available for 7K01DA051598-06
News and More
Related News Releases
No news release information available for 7K01DA051598-06
History
No Historical information available for 7K01DA051598-06
Similar Projects
No Similar Projects information available for 7K01DA051598-06